Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Human VTI1B aa 1-100. The exact sequence is proprietary.
Database link: Q9UEU0
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
This product is a recombinant rabbit monoclonal antibody.
Our Abpromise guarantee covers the use of ab184170 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P | 1/100. | |
WB | 1/1000 - 1/10000. Detects a band of approximately 27 kDa (predicted molecular weight: 27 kDa). | |
ICC/IF | 1/50. | |
Flow Cyt | 1/170. ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|
Immunohistochemical analysis of paraffin-embedded human ovarian carcinoma labeling VTI1B with ab184170 at 1:100 diluton and HRP polymer. Counterstained with Hematoxylin.
Immunofluorescent analysis of MCF7 cells (paraformaldehyde-fixed, 4%) labeling VTI1B with ab184170 at 1/50 dilution followed by Goat anti rabbit IgG (AlexaFluor® 488) secondary at 1/200 dilution and counter-stained with DAPI (blue).
Flow cytometric analysis of Hela cells (2% paraformaldehyde-fixed) labeling VTI1B with ab184170 at 1/170 dilution (red) or a rabbit IgG (negative) (green), followed by Goat anti rabbit IgG (FITC) secondary at 1/150 dilution.
ab184170 has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"